| Sep 17 |
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution
|
| Sep 11 |
Sonoma and EMC to co-market an expanded eye care product line
|
| Sep 11 |
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line
|
| Aug 28 |
Sonoma Pharmaceuticals to implement a reverse stock split
|
| Aug 28 |
Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock
|
| Aug 26 |
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff
|
| Aug 21 |
Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States
|
| Aug 11 |
Sonoma Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations
|
| Aug 9 |
Sonoma Pharmaceuticals reports Q1 results
|
| Aug 8 |
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results
|
